Premium
An Integrative Drug Repurposing Pipeline: Switching Viral Drugs to Breast Cancer
Author(s) -
Karuppasamy Ramanathan,
Verma Kanika,
Sequeira Velin Marita,
Basavanna Lokapriya Nandan,
Veerappapillai Shanthi
Publication year - 2017
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.25799
Subject(s) - drug repositioning , drug , repurposing , breast cancer , cancer , medicine , rosuvastatin , drug resistance , drug discovery , cancer research , pharmacology , biology , bioinformatics , ecology , microbiology and biotechnology
ABSTRACT The growing incidence rate of breast cancer, coupled with cellular chemotherapeutic resistance, has made this disease one of the most prevalent cancers among women worldwide. Despite the recent efforts to understand the underlying cause of the resistance due to mutation, there are no feasible tactics to overcome this bottleneck. This issue could be addressed by the concept of polypharmacology‐disguising drugs present in the pharmacopeia for novel purposes (drug repurposing). Of note, we have proposed a multi‐modal computational drug‐repositioning stratagem to predict drugs possessing anti‐proliferative effect. Our results suggest that Ombitasvir, a Hepatitis C NS5B polymerase inhibitor, could be “repurposed” for the control and prevention of beta‐tubulin‐driven breast cancers. J. Cell. Biochem. 118: 1412–1422, 2017. © 2016 Wiley Periodicals, Inc.